This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2022
  • /
  • 10
  • /
  • Incyte to acquire Villaris Therapeutics and with i...

Incyte to acquire Villaris Therapeutics and with it auremolimab a proposed treatment for Vitiligo

Read time: 1 mins
Published:5th Oct 2022

Incyte has announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. Its lead asset, auremolimab (VM6), an anti-IL-15R monoclonal antibody (mAb), is expected to enter clinical development in 2023

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.